Partnership marks AbbVie's entrance into the obesity field Agreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie's global infrastructure for developing and commercializing therapies for patients in need NORTH CHICAGO, Ill....
Read More Details
Finally We wish PressBee provided you with enough information of ( AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity )
Also on site :
- Morning Report — Texas braces for more flood danger after Hill Country tragedy
- ‘Rick and Morty’ Boss on How James Gunn and Zack Snyder Agreed to Parody Themselves and Their Dueling ‘Superman’ Takes (EXCLUSIVE)
- Bangladesh lawyers challenge ex-PM Hasina’s murder trial charges